PRZOOM - /newswire/ -
Issy les Moulineaux, Hauts-de-Seine, France, 2022/01/14 - Leader in the tracking of peripheral neuropathies, acquired by pioneers of connected health - Impeto-Medical.com / Withings.com
Withings, the pioneer of the connected health movement, has announced the acquisition of Impeto Medical (impeto-medical.com), a specialist in R&D, manufacturing and distribu7on of innova7ve medical devices for physicians.
This announcement incorporates the ownership of Impeto’s SUDOSCAN® technology, a leader in detec7ng and tracking peripheral neuropathies. The procurement will strengthen the research and development of new technologies for future Withings health products and services.
Established in 2005, Impeto Medical set new standards in detec7ng and tracking small ﬁber neuropathy - damage or dysfunc7on of small nerves - leveraging its proprietary SUDOSCAN® technology. The FDA cleared solu7on measures the ability of the sweat glands to release chloride ions in response to an electrical s7mulus on the palms of the hands and soles of the feet. The degenera7on of small nerve ﬁbers reduces sweat gland innerva7on and impairs sudomotor func7on. SUDOSCAN®eﬃcacy has been evaluated in the assessment of small ﬁber peripheral neuropathies in several diseases states, including diabetes, Chemotherapy-induced polyneuropathy, family amyloid polyneuropathy, and Fabry disease compared to gold-standard reference tests such as Skin biopsy or Quan7ta7ve Sudomotor Axon Reﬂex Test( QSART). Its solu7on has been licensed and embedded into of thousands of devices for pharmacies, medical oﬃces and hospitals worldwide.
“We are delighted to announce the acquisi9on of Impeto Medical as we welcome its experience and technologies into the Withings por?olio. The company and its team have been important partners to us in the past. Now, as part of Withings, we have an exci9ng opportunity to con9nue to deploy together their exper9se and Sudoscan technology in the development of a variety of devices that have the poten9al for people to monitor and manage various disease states from the comfort of their home” said Mathieu Letombe, Withings CEO.
The ﬁrst Withings product to incorporate SUDOSCAN® technology will be Withings Body Scan recently announced during CES 2022. Following FDA clearance, Body Scan will provide at home analysis of biomarkers associated with common health condi7ons. With the ability to monitor segmental body composi7on, heart rate, and vascular age, it will further advance the smart scale category. With measurements that will assess nerve ac7vity and heart rhythm using a 6-lead ECG, Body Scan goes beyond weight management to become an unprecedented in-home connected health sta7on that can help users take proac7ve measures.
As part of the deal, Withings has acquired all Impeto technology IP and patent. Impeto Medical staff has become a full part of Withings. Exis7ng Impeto Medical customers will con7nue to be provided
with full support.
Established in 2008, Withings (withings.com), is a world leader in connected health technology. Its team of engineers, data scien7sts, and healthcare professionals have enthused everyday, elegant lifestyle objects with medical and wellness capabili7es to efficiently track health vitals. Its range of in-home devices can monitor more than 20 health parameters and are used daily by millions of people worldwide. Its porbolio of devices includes connected scales, hybrid watches, smart thermometers, blood pressure monitors, and sleep trackers to empower individuals to take back control of their health and track medical and wellness data.